Europan 200 Mg 200 mg Tablet
PDF Leaflet Revision Date: 22 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced and/or metastatic renal cell carcinoma.
Dosage (summary)
800 mg orally once daily; modify in 200 mg increments based on tolerability.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use with caution; potential risk to fetus; not established in breastfeeding.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Grapefruit juice
- Simvastatin
Contraindications
- Hypersensitivity to pazopanib
Common side effects
- Hypertension
- Hypothyroidism
- Proteinuria
- Diarrhoea
- Fatigue
Counselling Points
- Take without food (1 hour before or 2 hours after meals)
- Monitor liver function
- Use contraception during treatment
Serious warnings
- Hepatic failure
- Hypertensive crisis
- PRES/RPLS
- Cardiac dysfunction
- GI perforations
Important Disclaimer
The Europan 200 Mg 200 mg Tablet professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
